Is Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Stock About to Get Hot Friday?

Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) stock has fallen 6.08% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Bio-Rad Laboratories, Inc. Class A Common Stock has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on BIO!

See Full BIO Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With BIO Stock Today?

Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) stock has fallen -1.11% while the S&P 500 has gained 0.32% as of 2:54 PM on Friday, Sep 22. BIO is down -$3.95 from the previous closing price of $357.30 on volume of 62,258 shares. Over the past year the S&P 500 is higher by 14.62% while BIO is down -18.01%. BIO lost -$14.72 per share in the over the last 12 months.

More About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier. Click Here to get the full Stock Report for Bio-Rad Laboratories, Inc. Class A Common Stock stock.